T Cell Invigoration is Associated with the Clinical Response to Anti-PD-1-Based Immunotherapy in Non-Small Cell Lung Cancer

PURPOSE: Immune checkpoint inhibitors (ICIs) have been developed for clinical application and proven effective for non-small cell lung cancer (NSCLC). Blockade of the programmed cell death 1 (PD-1) protein can partially reinvigorate circulating exhausted-phenotype CD8+ T cells (Tex cells) in preclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Hui, Weng, Gui Zhen, Sun, Li Na, Pan, Zhang Chi, Zhang, Lu, Chen, Qiang, Shi, Chun Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576507/
https://www.ncbi.nlm.nih.gov/pubmed/37842130
http://dx.doi.org/10.2147/CMAR.S415629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576507/
https://www.ncbi.nlm.nih.gov/pubmed/37842130
http://dx.doi.org/10.2147/CMAR.S415629

Ejemplares similares